title: Limited maximal flow rate of target-controlled remifentanil infusion and induced cough.
abstract: This study evaluated the effect of limiting maximal infusion-pump flow rate on suppression of remifentanil-induced cough during target-controlled infusion. Two hundred and ten patients were randomly assigned to receive remifentanil at an effect-site concentration of 4.0 ng.ml(-1) with maximal flow rate limited to 100 (group R(100)), 200 (group R(200)), or 1200 ml.h(-1) (group R(1200)). The number of episodes of cough were recorded and graded as mild (1-2), moderate (3-4), or severe (5 or more). The incidence of cough was 2.9% in group R(100), 5.7% in group R(200) and 25.7% in group R(1200). Patients in group R(100) and R(200) had a significantly lower incidence of cough than those in group R(1200) (p < 0.05). Zero, two and five patients coughed a moderate amount in groups R(100), R(200) and group R(1200), respectively (p < 0.05). Limiting maximal infusion rate during remifentanil TCI suppressed remifentanil-induced cough.
authors.affiliation: Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Korea.
authors.forename: S K
authors.initials: SK
authors.lastname: Min
authors.forename: D H
authors.initials: DH
authors.lastname: Kim
authors.forename: H B
authors.initials: HB
authors.lastname: Cho
authors.forename: B K
authors.initials: BK
authors.lastname: Moon
authors.forename: J Y
authors.initials: JY
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D000996:Antitussive Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D003371:Cough / Q000139:chemically induced* / Q000453:epidemiology; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010149:Postoperative Pain / Q000150:complications / Q000188:drug therapy; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D000077208:Remifentanil; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D000996:Antitussive Agents; D010880:Piperidines; D000077208:Remifentanil